This evidence summary reviewed 4 randomised trials of Truvada (emtricitabine/tenofovir disoproxil 200 mg/245 mg) for pre-exposure prophylaxis (PrEP) of HIV in either HIV-negative men or transgender women who have sex with men, or HIV-negative individuals in a heterosexual partnership with a person already infected with HIV.
05 October 2016 | NICE
National, state and local races will affect HIV prevention, care and treatment—both at home and abroad.
04 October 2016 | Poz
Mark Heywood writes: This will be our country’s fifth national AIDS plan since democracy. It is certainly the most critical. This is the do or die plan. Literally. I’ve been involved in all five so please allow me to reflect on why this one is so important.
03 October 2016 | Spotlight
Getting PrEP information in front of family planning providers could make a big difference in women's access to the HIV prevention tool. Right now, 60% of women access primary care through family planning providers, yet only about 4% of family planning providers have ever prescribed PrEP.
27 September 2016 | The Body Pro
A new CDC study examining the first decade of HIV antiretroviral therapy (ART) scale-up in Mozambique revealed fewer people are dying from HIV in recent years, likely due to more patients starting treatment at earlier disease stages. The analysis also found that people who more recently began ART were less likely to remain engaged in HIV treatment and care over time. The analysis highlights participation in community ART support groups (CASGs), small groups of patients who support each other to remain on ART, as an effective strategy to significantly reduce loss to follow up.
20 September 2016 | CDC
A new 2016 edition of MEDFASH's " HIV in Primary Care" has been published. An essential guide for GPs, practice nurses and other members of the primary healthcare team.
12 September 2016 | MEDFASH press release
With fewer than 10 weeks until the November general election, there is no shortage of topics for the presidential candidates to discuss and debate. On the health care front, the Kaiser Health Tracking Poll: August 2016 indicates that, though health-related concerns have largely taken a backseat in media coverage, a number of these issues -- including HIV -- are priorities for voting Americans.
12 September 2016 | The Body
The influential Health Select Committee has said a dispute with NHS England about HIV-preventing drugs has shown flaws in the government’s localised health legislation.
01 September 2016 | Pink News
Truvada, an expensive breakthrough drug that prevents people from getting HIV won't be funded by taxpayers in Australia this year, the nation's drug funding panel has ruled. A Department of Health spokeswoman said the PBAC understood "this is an important new prevention medication for HIV", but decided the price set by the drug's sponsor, Gilead Sciences, was too high and a proposal to limit subsidy to a small subset of the "at risk" group was not feasible.
"In its deliberations the PBAC indicated a substantial price reduction would be needed to make Truvada available for PrEP for the whole 'at risk' population, but noted that Truvada for PrEP could represent value for money in the broader population at a substantially lower price," the spokeswoman said.
19 August 2016 | Sydney Morning Herald
In pointed remarks, Germany’s cost-effectiveness watchdog has criticised an effort by European regulators to accelerate approval for new medicines by limiting its requirements for evidence. The concerns raised by the agency come as regulators on both side of the Atlantic increasingly look to such approaches to get new drugs to patients with unmet medical needs. At issue is a proposal called adaptive pathways, a term used to describe a method for jumpstarting drug approvals for select patient populations. Two years ago,an EMA pilot programme was launched to compare initial data used for approval with so-called “real world” data, which is subsequently gathered after the medicines are in use.
18 August 2016 | STAT